VEA
IMGN

Virtus ETF Advisers’s Immunogen Inc IMGN Stock Holding History

Virtus ETF Advisers’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,174
Closed -$273K – 468
2023
Q3 		$273K Sell
17,174
-2,218
-11% -$36.9K 0.17% 213
2023
Q2 		$366K Sell
19,392
-40,181
-67% -$474K 0.22% 144
2023
Q1 		$229K Buy
59,573
+1,052
+2% +$4.48K 0.13% 296
2022
Q4 		$290K Buy
58,521
+26,180
+81% +$142K 0.15% 283
2022
Q3 		$155K Buy
32,341
+235
+0.7% +$1.24K 0.06% 349
2022
Q2 		$144K Buy
32,106
+7,260
+29% +$31.5K 0.05% 325
2022
Q1 		$118K Sell
24,846
-1,477
-6% -$8.18K 0.05% 271
2021
Q4 		$195K Sell
26,323
-5,929
-18% -$36.8K 0.07% 218
2021
Q3 		$183K Sell
32,252
-1,691
-5% -$9.77K 0.08% 293
2021
Q2 		$224K Sell
33,943
-7,416
-18% -$51.7K 0.09% 264
2021
Q1 		$335K Buy
41,359
+724
+2% +$5.91K 0.14% 217
2020
Q4 		$262K Sell
40,635
-29,578
-42% -$173K 0.11% 294
2020
Q3 		$253K Sell
70,213
-9,582
-12% -$38.7K 0.13% 261
2020
Q2 		$367K Sell
79,795
-20,636
-21% -$87.8K 0.17% 244
2020
Q1 		$342K Sell
100,431
-14,644
-13% -$64K 0.14% 211
2019
Q4 		$587K Sell
115,075
-12,521
-10% -$42.5K 0.1% 192
2019
Q3 		$309K Sell
127,596
-7,108
-5% -$18.9K 0.06% 197
2019
Q2 		$292K Buy
134,704
+84,659
+169% +$200K 0.06% 227
2019
Q1 		$136K Sell
50,045
-6,826
-12% -$29.6K 0.29% 97
2018
Q4 		$273K Buy
56,871
+11,759
+26% +$71.4K 0.05% 141
2018
Q3 		$427K Sell
45,112
-32,253
-42% -$310K 0.04% 150
2018
Q2 		$753K Sell
77,365
-35,182
-31% -$371K 0.67% 67
2018
Q1 		$1.18M Buy
112,547
+58,570
+109% +$579K 1.03% 21
2017
Q4 		$346K Sell
53,977
-16,058
-23% -$99K 0.43% 97
2017
Q3 		$536K Buy
70,035
+6,406
+10% +$42.6K 0.07% 83
2017
Q2 		$452K Buy
+63,629
New +$291K 0.07% 75
2016
Q4 		– Sell
-70,796
Closed -$190K – 193
2016
Q3 		$190K Hold
70,796
– – 0.09% 142
2016
Q2 		$218K Buy
70,796
+51,539
+268% +$323K 0.16% 128
2016
Q1 		$164K Buy
+19,257
New +$163K 0.23% 111

Other funds holding IMGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Virtus ETF Advisers's IMGN Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Immunogen Inc (IMGN) in Q4 2023, closing a stake of 17,174 shares — an estimated $273K sold.

Virtus ETF Advisers first reported a position in IMGN in Q1 2016 and held it in 29 quarters. The position peaked at $1.18M in Q1 2018. 327 funds tracked by Wall St. Rank hold IMGN as of Q4 2023.

  • Virtus ETF Advisers reported no remaining Immunogen Inc position as of Q4 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 17,174 Immunogen Inc shares in Q4 2023, an estimated $273K.
  • Virtus ETF Advisers first reported a position in Immunogen Inc in Q1 2016 and held it in 29 quarters.
  • Virtus ETF Advisers's Immunogen Inc position peaked at $1.18M in Q1 2018.
  • 327 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.